Genentech at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Genentech exhibits at Booth 439 at ASH 2026 in New Orleans. Its presence centres on bispecific antibodies in blood cancers, supporting a symposium on their best use in non-Hodgkin lymphoma through second-opinion case reviews. It also supports one answering community oncologists' questions about BCMA-directed antibody-drug conjugates and bispecific antibodies in myeloma.
| Organization | ASH 2026 Attendance |
|---|---|
Genentech South San Francisco, CA | |
Biotechnology company and member of the Roche Group, with medicines for blood cancers and hemophilia. | Booth Exhibiting at Booth 439 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know Answers to community oncologists' top questions on B-cell maturation antigen-targeted antibody-drug conjugates and bispecific antibodies in multiple myeloma. Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. |
Instantly find 20 buyers from Genentech
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction